Palo Santo

Xylo Bio is a drug development company focused on next-generation psychedelic-inspired therapeutics for psychiatric and neurological disorders. Through a psychedelic therapeutic platform, it aims to develop non-hallucinogenic, rapid-acting medicines that can be widely available and provide improvements over current SSRI treatments. The company seeks to rewire neural circuits and restore brain function, enabling clinicians to optimize care and expand treatment options beyond traditional antidepressants.

Reunion Neuroscience is a clinical-stage pharmaceutical company focused on developing therapeutic solutions for underserved mental health conditions. Its lead asset, RE104, is a proprietary psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depression and other mental health conditions.

Journey Clinical offers an online platform that supports independent psychotherapists in expanding their practices to include ketamine-assisted psychotherapy. The company facilitates prescription services, enabling mental health professionals to provide safe and effective psychedelic therapy to patients.

Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company based in New York, focused on developing innovative psychotropic drugs to address mental health issues. Founded in 2019, the company specializes in creating novel compounds that enhance the benefits of traditional psychedelics, improving parameters such as safety, tolerability, duration, and efficacy. Gilgamesh targets a range of neuropsychiatric conditions, including depression, anxiety, substance use disorders, and stress-related issues. With the growing global mental health crisis, the company aims to accelerate the development of new treatments that meet the urgent need for effective solutions in mental health care, leveraging its expertise in medicinal chemistry and drug development.

Founded in 2021, Sensorium Therapeutics is a Boston-based company developing novel FDA-approved psychoactive medicines using its proprietary drug discovery platform. The platform employs artificial intelligence and computational methods to accelerate the identification of new drug candidates for treating brain and mental health conditions.

Kadence Bio is a clinical-stage life sciences company developing novel therapeutics, with a focus on small molecule programs addressing sexual and mental well-being. Its lead compound KH-001 is being developed as a treatment for premature ejaculation, reflecting the company’s aim to provide additional options for patients and expand therapeutic opportunities in areas with significant unmet need.

Fluence offers continuing education and certificate programs in psychedelic integration and psychedelic-assisted therapy. Our programs are designed for licensed professionals and advanced graduate students who have an opportunity to work with patient populations. Although none of our courses have specific prerequisites, a basic working knowledge of the mental health field and practice of psychotherapy is helpful. Our programs are interactive; we engage in discussion, demonstration, self-reflection exercises, and role plays. Some of our classes and programs are reserved for licensed clinicians, but many are open to anyone who wishes to attend.

Wavepaths, established in 2018 and based in London, specializes in developing accessible technology for psychedelic therapy. The company creates personalized soundtracks using intelligent technologies and immersive media, aiming to facilitate inner exploration and emotional reconnection during drug-free therapeutic sessions. Their offerings span the fields of information technology, healthcare, and personal health.

Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel neuroplasticity-promoting therapeutics—to better treat mental health disorders at scale. The company was founded in 2019 and is headquartered in Boston, Massachusetts.

Journey Clinical offers an online platform that supports independent psychotherapists in expanding their practices to include ketamine-assisted psychotherapy. The company facilitates prescription services, enabling mental health professionals to provide safe and effective psychedelic therapy to patients.

Founded in 2014, Beckley Psytech is a UK-based company dedicated to developing psychedelic medicines for treating mental health disorders. It focuses on rigorous scientific research and clinical-stage drug development, aiming to provide innovative treatments for conditions like depression and anxiety.

Founded in 2019, Ksana Health specializes in digital mental health solutions. Its platform collects user data related to mental health and facilitates its transfer to healthcare practitioners for improved patient care.

Eleusis is a clinical stage life science company focused on harnessing the therapeutic potential of serotonin 2A receptor agonists, commonly known as psychedelics. The company aims to develop innovative psychedelic drug therapies that address unmet medical needs, particularly in the field of psychiatry and beyond. Eleusis is advancing a novel approach to transform psilocybin into a safe, effective, convenient, and affordable treatment option for depression. By doing so, the company seeks to provide healthcare providers and pharmaceutical companies with viable alternatives to conventional therapies, thereby broadening the scope of treatment options available to patients.